JP2023518299A5 - - Google Patents

Info

Publication number
JP2023518299A5
JP2023518299A5 JP2022556587A JP2022556587A JP2023518299A5 JP 2023518299 A5 JP2023518299 A5 JP 2023518299A5 JP 2022556587 A JP2022556587 A JP 2022556587A JP 2022556587 A JP2022556587 A JP 2022556587A JP 2023518299 A5 JP2023518299 A5 JP 2023518299A5
Authority
JP
Japan
Prior art keywords
compound
cancer
heteroaryl
salt
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518299A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/023512 external-priority patent/WO2021189051A1/en
Publication of JP2023518299A publication Critical patent/JP2023518299A/ja
Publication of JP2023518299A5 publication Critical patent/JP2023518299A5/ja
Priority to JP2025139537A priority Critical patent/JP2025183239A/ja
Pending legal-status Critical Current

Links

JP2022556587A 2020-03-20 2021-03-22 小分子エナンチオマーによるアンドロゲン受容体調節 Pending JP2023518299A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025139537A JP2025183239A (ja) 2020-03-20 2025-08-25 小分子エナンチオマーによるアンドロゲン受容体調節

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062992668P 2020-03-20 2020-03-20
US62/992,668 2020-03-20
PCT/US2021/023512 WO2021189051A1 (en) 2020-03-20 2021-03-22 Androgen receptor regulation by small molecule enantiomers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025139537A Division JP2025183239A (ja) 2020-03-20 2025-08-25 小分子エナンチオマーによるアンドロゲン受容体調節

Publications (2)

Publication Number Publication Date
JP2023518299A JP2023518299A (ja) 2023-04-28
JP2023518299A5 true JP2023518299A5 (enExample) 2024-04-03

Family

ID=77771673

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022556587A Pending JP2023518299A (ja) 2020-03-20 2021-03-22 小分子エナンチオマーによるアンドロゲン受容体調節
JP2025139537A Pending JP2025183239A (ja) 2020-03-20 2025-08-25 小分子エナンチオマーによるアンドロゲン受容体調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025139537A Pending JP2025183239A (ja) 2020-03-20 2025-08-25 小分子エナンチオマーによるアンドロゲン受容体調節

Country Status (4)

Country Link
US (1) US20260103470A1 (enExample)
EP (1) EP4121044A4 (enExample)
JP (2) JP2023518299A (enExample)
WO (1) WO2021189051A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023518299A (ja) * 2020-03-20 2023-04-28 ユニバーシティー オブ サウザン カリフォルニア 小分子エナンチオマーによるアンドロゲン受容体調節
US12552806B2 (en) 2020-03-20 2026-02-17 University Of Southern California Androgen receptor regulation by small molecule enantiomers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
TWI263640B (en) * 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2008157291A2 (en) * 2007-06-15 2008-12-24 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (3Aα, 4β, 5α, 7β, 7Aα)-4-(OCTAHYDRO-5-ETHYLSULFONAMIDO-4,7-DIMETHYL-1,3-DIOXO-4,7-EPOXY-2H-ISOINDOL-2-YL)-2-(TRIFLUOROMETHYL)BENZONITRILE AND METHOD OF PREPARATION
WO2011029782A1 (en) * 2009-09-11 2011-03-17 Bayer Schering Pharma Aktiengesellschaft Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
WO2020211822A1 (zh) * 2019-04-18 2020-10-22 成都海创药业有限公司 一类靶向降解雄激素受体的双功能嵌合体杂环化合物及其用途
JP2023518299A (ja) * 2020-03-20 2023-04-28 ユニバーシティー オブ サウザン カリフォルニア 小分子エナンチオマーによるアンドロゲン受容体調節

Similar Documents

Publication Publication Date Title
JP6434482B2 (ja) 置換アシルアニリドおよびそれらの使用方法
JP5484914B2 (ja) 核内受容体結合剤
CN103251579B (zh) 取代的n-酰基苯胺及其使用方法
CN109790135B (zh) 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
US20130034562A1 (en) Selective androgen receptor modulators for treating diabetes
RU2003115490A (ru) Амидные производные в качестве антагонистов nmda рецептора
AR037329A1 (es) Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos
JP2008508214A (ja) 女性の性障害の治療用ピペラジン誘導体
CN103619330A (zh) 用于治疗糖尿病的选择性雄激素受体调节剂
JP2023518299A5 (enExample)
US20190055192A1 (en) Selective androgen receptor modulator and methods of use thereof
US20240390399A1 (en) Materials and methods for suppressing and/or treating bone related diseases and symptoms
JP2015502371A5 (enExample)
JP2024542881A5 (enExample)
US10053418B2 (en) Selective androgen receptor modulator and methods of use thereof
JP2023552862A5 (enExample)
WO2019037755A1 (zh) 一类干扰素调节剂及其制备方法和用途
IE66601B1 (en) 2,3-Dihydro-1-(pyridinylamino)-indoles a process for their preparation and their use as medicaments
CN1859846A (zh) 白屈菜赤碱、其类似物及其在治疗躁郁症和其他认知紊乱中的应用
RU2002107421A (ru) Алкоксизамещенные бензимидазольные соединения, содержащие их фармацевтические препараты и способы их применения
JP2010528032A (ja) 甲状腺癌の処置のためのｒａｆ阻害剤
AU2013219238C1 (en) Nuclear receptor binding agents
CS277691A3 (en) 3-/1h-indazol-3-yl/-4-pyridinamines, process and intermediates for their preparation and their application as medicaments
JP2024512024A5 (enExample)
KR102792443B1 (ko) Cdk를 저해하는 신규 피롤로피리미디논 카복사미드 화합물, 이의 입체이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암 치료용 약학적 조성물